
MIT Technology Review @techreview
[SPONSORED] Integrating AI in drug development trials offers clear benefits from faster time to market, reduced risks, lowered costs, and fewer burdens on patients, says senior VP of Medidata AI, Arnaub Chatterjee. Listen here. (With @Medidata) https://t.co/OEEbypf5dZ — PolitiTweet.org